Charting the Course of Targeted α Therapy With First-in-Human, Postadministration Image-Guided Dosimetry and Response Assessment of 212 Pb-VMT-α-NET in Metastatic Neuroendocrine Tumors.

Abstract: 212 Pb emerges as a compelling in vivo α-particle generator for targeted α therapy due to its favorable half-life ( t1/2 = 10.6 hours) aligning with the biological half-lives of small peptides and its potent α-particle emissions within the decay series. However, one of the challenges with 212 Pb is to perform appropriate image-guided dosimetry. To date, all the data have been extrapolated from its imaging analog, 203 Pb. We present the first-in-human posttherapy image-guided dosimetric estimates of a single cycle of 212 Pb VMT-α-peptide, administered in a 41-year-old woman with an advanced grade 2 NET. The patient also demonstrated partial response on treatment.
Competing Interests: Conflicts of interest and sources of funding: M.K.S. is inventor of the peptide VMT-α-NET and chief science officer of Prospective Therapeutics. There is no conflict of interest with respect to the other authors. The 224 Ra/ 212 Pb generator and the VMT-α-NET peptide were provided by Perspective Therapeutics. The investigators have not received any fee or financial indemnity from Perspective Therapeutics.
(Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc.)